Furthermore, assessing the levels of Treg and CD4+T cells in HER-2 (+) patients can be valuable for monitoring the condition of breast cancer patients and predicting the efficacy of anti-HER-2 treatment. The gene discussed is ERBB2; the disease is breast carcinoma.